Table 2. . Updates in neoadjuvant therapy for esophageal, gastric and gastroesophageal junction cancer.

Study	Trial	Cancer type	Eligibility	Phase	Number of patients (n)	Timing	Intervention	End point	Ref.
Shapiro et al.	CROSS	Esophageal/GEJ	cT12N1M0 or T2–3N0–1M0	III	368	Neoadjuvant	CP + surgery vs surgery alone	Median OS 48.6 vs 24.0 mo (p = 0.003)	[6]
Goodman et al.	CALGB80803	Esophageal/GEJ	cT3–4 or N+	II	257	Adjuvant	FOLFOX-6 or CP, PET nonresponders crossed over to alternate chemotherapy	pCR for PET-nonresponders pCR 15.6%	[9]
Al-Batran et al.	FLOT4-AIO	Gastric/GEJ	cT2+ and/or cN+	II/III	300	Adjuvant	FLOT vs ECF/ECX	3y OS 57 vs 48%	[98]

CP: Chemotherapy; ECF: Epirubicin, cisplatin, fluorouracil; ECX: Epirubicin, cisplatin, capecitabine; FLOT: Fluorouracil, leucovorin, oxaliplatin, docetaxel; GEJ: Gastroesophageal junction; mo: Month; OS: Overall survival; pCR: Pathologic complete response rate; PET: Positron emission technology.